英国着色性干皮病患者眼表活检的回顾性观察病例系列
该研究回顾性分析了英国国家着色性干皮病(XP)服务2010至2019年接诊的108例XP患者,其中17例至少接受过一次眼表活检,13例共45份活检样本可用。结果显示,65%的活检来自互补亚组C(XP-C)患者,非定位活检中46%显示眼表鳞状上皮肿瘤,67%见一般非异型增生性损伤, Melanocytic改变在非定位活检中占25%、定位活检中占81%;47%的活检结果无需额外治疗,需治疗者中50%接受丝裂霉素C。该系列为已报道的最大XP眼表活检队列,揭示了眼表黑素细胞性、退行性和炎症性改变的背景,XP-C患者表现最严重。
要点
- XP患者眼表活检可显示鳞状上皮肿瘤、黑素细胞改变及退行性/炎症性改变。
- XP-C互补亚组患者眼表受累最严重,多数活检来自该亚组。
- 约半数活检结果需额外治疗,其中一半使用丝裂霉素C。
核心结论
- XP患者眼表存在黑素细胞性、退行性和炎症性改变背景,XP-C患者表现最严重。
- XP患者眼表活检组织病理学解读及后续治疗规划存在挑战。
研究设计与样本
- 回顾性观察性病例系列,分析英国国家XP服务2010至2019年接诊的全部XP患者病历。
- 108例XP患者中17例至少接受一次眼表活检,13例共45份活检样本可用。
主要发现
- 45份活检样本中65%来自互补亚组C(XP-C)患者。
- 非定位活检中67%以肿块为指征,46%显示眼表鳞状上皮肿瘤。
- 非定位活检中67%见一般非异型增生性损伤,黑素细胞改变在非定位活检中占25%、定位活检中占81%。
- 47%的活检结果无需额外治疗;需治疗者中50%接受丝裂霉素C。
临床怎么用
- 对XP患者眼表异常应保持警惕,活检可发现鳞状上皮肿瘤及黑素细胞改变。
- XP-C患者眼表改变最严重,随访和干预需更积极。
- 活检结果解读需结合临床,约半数需额外治疗,丝裂霉素C为常用选择。
局限性
- 回顾性研究,样本量有限(17例活检,13例45份样本)。
- 组织病理学解读存在挑战,可能影响结果判读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: To describe the results of all ocular surface biopsies performed on patients with xeroderma pigmentosum (XP) under the care of the UK Nationally Commissioned XP Service as well as the treatment of any subsequent ocular surface conditions diagnosed. METHODS: Retrospective analysis of medical records. All patients with XP seen by the service from 2010 to 2019 were included and those with ocular surface biopsies were identified. Data was collected on demographics, complementation subgroup (A-G and V), biopsy details, histopathological analysis and subsequent management. RESULTS: Of 108 patients seen in our service, 17 underwent at least one ocular surface biopsy. 45 biopsy samples were available from 13 patients of which 65% were performed on patients from complementation subgroup C (XP-C). Biopsies were categorised as either non-mapping (clinically abnormal ocular surface tissue) or mapping (multiple sites including clinically normal tissue). 67 percent of non-mapping biopsies had a mass as their indication and 46% showed ocular surface squamous neoplasia. General non-dysplastic damage was seen in 67% of non-mapping biopsies and melanocytic changes were seen in 25% of non-mapping and 81% of mapping biopsies. 47 percent of biopsy outcomes required no additional treatment but, of those that did, 50% received mitomycin C. CONCLUSIONS: This is the largest reported series of ocular surface biopsies in patients with XP. It identifies a background of ocular surface melanocytic, degenerative and inflammatory changes, with patients with XP-C showing the most severe effects. We highlight challenges faced in interpreting their histopathology and in planning subsequent treatments.
引用
- Vekinis J, Morley AMS. Ocular surface biopsies of patients with xeroderma pigmentosum in the United Kingdom: a retrospective observational case series. Br J Ophthalmol. 2020. PMID: 32892165. doi:10.1136/bjophthalmol-2020-316125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。